Chris Haskins - Publications

Affiliations: 
Indiana University, Bloomington, Bloomington, IN, United States 

4 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Henderson-Redmond AN, Nealon CM, Davis BJ, Yuill MB, Sepulveda DE, Blanton H, Piscura MK, Zee ML, Haskins CP, Marcus DJ, Mackie K, Guindon J, Morgan DJ. c-Jun N terminal kinase signaling pathways mediate cannabinoid tolerance in an agonist-specific manner. Neuropharmacology. 107847. PMID 31758947 DOI: 10.1016/j.neuropharm.2019.107847  0.72
2016 Marcus DJ, Zee ML, Davis BJ, Haskins CP, Andrews MJ, Amin R, Henderson-Redmond AN, Mackie K, Czyzyk TA, Morgan DJ. Mice Expressing a "Hyper-Sensitive" Form of the Cannabinoid Receptor 1 (CB1) Are Neither Obese Nor Diabetic. Plos One. 11: e0160462. PMID 27501235 DOI: 10.1371/journal.pone.0160462  0.56
2014 Wu CS, Morgan D, Jew CP, Haskins C, Andrews MJ, Leishman E, Spencer CM, Czyzyk T, Bradshaw H, Mackie K, Lu HC. Long-term consequences of perinatal fatty acid amino hydrolase inhibition. British Journal of Pharmacology. 171: 1420-34. PMID 24730060 DOI: 10.1111/bph.12500  0.56
2012 Atwood BK, Wager-Miller J, Haskins C, Straiker A, Mackie K. Functional selectivity in CB(2) cannabinoid receptor signaling and regulation: implications for the therapeutic potential of CB(2) ligands. Molecular Pharmacology. 81: 250-63. PMID 22064678 DOI: 10.1124/mol.111.074013  0.56
Show low-probability matches.